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Inﬂammatory cytokines, such as tumor necrosis factor and the members of the interferon family, are
potent mediators of the innate anti-viral immune response. The intracellular anti-viral states resulting
from treatment of cultured cells with each of these molecules independently has been well studied;
but, within complex tissues, the early inﬂammatory response is likely mediated by simultaneously
expressed mixtures of these, and other, protective anti-viral cytokines. Such cytokine mixtures have been
shown to induce potently synergistic anti-viral responses in vitro which are more complex than the
simple summation of the individual cytokine response proﬁles. The physiological role of this ‘cytokine
synergy’, however, remains largely unappreciated in vivo. This brief commentary will attempt to summa-
rize the potential effects and mechanisms of anti-viral cytokine synergy as well as present several ‘real-
world’ applications where this phenomenon might play an important role.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Inﬂammatory cytokines, such as the type-I and type-II interfer-
ons (IFNs) and tumor necrosis factor (TNF), are small secreted pro-
teins which, together with their cognate receptors and
downstream signaling pathways, play a key role in the innate
restriction of invading pathogens such as viruses. In past years, a
tremendous amount of effort has been put into elucidating the
molecular events triggered by the interaction of these cytokines
with their target receptors [1,2]. However, while it is technically
straightforward to study the functions of these molecules indepen-
dently, in vivo, the innate responses to invading pathogens are
much more likely to involve simultaneous interactions of respond-
ing cells with complex cytokine mixtures. For example, for many
years our lab has investigated the host tropism determinants of a
rabbit speciﬁc leporipoxvirus called myxoma virus (MYXV) [3,4].
MYXV infection is highly lethal in the European rabbit; however,
all other tested species, including humans and mice, are able to
readily control viral infection. In humans this control is mediated
by the rapid secretion of multiple cytokines, including TNF and
IFN-a, from infected myeloid cells, such as macrophages, soon after
virus challenge [5]. Cells adjacent to these activated myeloid cells
are therefore subjected to a complex milieu made up of multipler Ltd.
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identiﬁed are sufﬁcient to completely ablate viral replication in
primary human cells; however, the combination of multiple
cytokines together induces a unique cellular transcriptional pro-
gram which displays signiﬁcantly greater anti-viral effects than
treatment with the individual cytokines alone can produce [6]. This
‘‘greater than the sum of its parts’’ response has been observed in a
variety of other systems and has been termed ‘cytokine synergy’
[7]. Unfortunately, due to the complexity involved in analyzing
the huge number of cytokine combinations that could potentially
occur in vivo, the understanding of cytokine synergy has severely
lagged behind the study of the anti-viral states induced by the
individual proteins.
2. Anti-viral effects of cytokine synergy
The phenomenon of anti-viral cytokine synergy can be traced
back to a report by Wong et al. in 1986 demonstrating that the rep-
lication of both RNA and DNA viruses could be synergistically
blocked in a variety of cells by treatment with combinations of
either TNF/IFN-b or TNF/IFN-c [8]. Since then, a variety of groups
have demonstrated that the replication of diverse viruses, includ-
ing: varicella zoster (VZV) [9], herpes simplex virus-2 (HSV2)
[8,10–12], Epstein Barr virus (EBV) [13], vesicular stomatitis virus
(VSV) [7], severe acute respiratory syncytia virus (SARS) [14], and
others (reviewed in [15]), can be synergistically restricted by treat-
ing cells with various combinations of: TNF, IL1-b, type-I IFN, and/
or type-II IFN. Unfortunately, the molecular events mediating viral
restriction by these synergistic anti-viral states are extremely
complex and diverse and have therefore proven difﬁcult to
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TNF and IFN-c inhibits human cytomegalovirus replication at a
stage prior to viral early gene expression [8,12] while a similar
treatment allows murine cytomegalovirus to progress through
DNA replication and late gene expression [16,17]. In fact, various
groups have observed restriction of viral replication following
treatment with various combinations of cytokines at virtually
every point in the viral replication cycle, including: binding/entry
[8,12,18], early viral gene transcription [9,19,20], assembly [21],
and/or egress [16,17]. These data suggest that multiple mecha-
nisms are likely involved in the restriction of viral replication by
anti-viral synergistic cytokine responses. Additionally, the anti-vir-
al effects of cytokine synergy have been shown to differ when
slightly different doses of cytokines and/or virus are used [12,22],
or when the cytokines are added at various times in relation to
either virus or each other [7] (and our unpublished observations).
Signiﬁcant new research will therefore be needed to deconstruct
the molecular details of the complex modulatory effects of
cytokine synergy on the replication of various viruses. This will
be particularly true within the virus-infected host where the com-
plete list of functional anti-viral cytokines induced in situ may not
yet be determined.3. Mechanisms of synergy
A report by Peng et al. [23] proposed two distinct mechanistic
forms of synergy, coined ‘synergy by cooperative action’ and ‘syn-
ergy by independent action’ (Fig. 1). ‘Synergy by independent
action’ occurs when two cytokines induce distinctive sets of host
response genes whose combined effector functions synergistically
inhibit viral replication. In contrast, ‘synergy by cooperative action’
occurs when treatment with two cytokines synergisticallyFig. 1. Mechanisms of anti-viral cytokine synergy. Three distinct, but non-exclusive, mec
which treatment with multiple cytokines enhances the level of expression of one or mo
proteins induced to a low level functionally synergize to block viral replication. ‘‘Syner
expression of anti-viral proteins not induced by treatment with the individual cytokines.
any of the individual cytokines alone. Each response can occur individually or in combienhances the expression levels of anti-viral genes normally in-
duced to lower levels by one, or both, of the individual cytokines.
For example, treatment of primary human ﬁbroblasts with IFN-b
has been shown to induce expression of OAS1, as one of a much
larger set of interferon stimulated genes (ISGs), while treatment
of these same cells with IFN-c induces a related but distinct set
of ISGs that includes expression of INDO. In ‘synergy by indepen-
dent action’ treatment of ﬁbroblasts with both cytokines would in-
duce expression of both OAS1 and INDO to similar levels seen by
the single cytokine treatments; however, simultaneous expression
of both ISGs would synergistically inhibit viral replication. In con-
trast, in ‘synergy by cooperative action’ treatment with both cyto-
kines would induce expression of OAS1 and/or INDO to much
higher levels than are observed following treatment with either
cytokine alone, thus improving each individual protein’s ability
to block viral replication.
We have recently deﬁned a third potential mechanism of syn-
ergy related to ‘synergy by cooperative action’ which we have
termed ‘synergy by cooperative induction’. In this form of synergy,
treatment of cells with multiple cytokines induces a unique set of
response genes that are not induced by either cytokine alone [6]
(Fig. 1). Induction of these new genes can then inhibit viral replica-
tion through novel effector mechanisms not present following
treatment with the individual cytokines.
Importantly, these mechanisms are not thought to be mutually
exclusive and it is therefore likely that two or even all three
mechanisms might occur within a single cell. Additionally, it is
not known whether synergy occurs in addition to the responses
mediated by the individual cytokines or instead of these responses.
Therefore, cells reacting to treatment with multiple cytokines have
the potential to induce a myriad number of possible responses
including: a response to one or both individual cytokines, induc-hanisms of cytokine synergy have been proposed. ‘Synergy by cooperative action’ in
re anti-viral proteins. ‘Synergy by independent action’ in which multiple anti-viral
gy by cooperative induction’’ in which treatment with multiple cytokines induces
In each case, the anti-viral effects of the cytokine combination are more potent than
nation with any or all other potential responses.
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neous but distinct responses to the individual cytokines and one or
more synergistic responses.
To date, very little has been reported about the molecular
mechanism(s) mediating any of these forms of synergy. ‘Synergy
through cooperative action’ and ‘synergy through cooperative
induction’ appear to occur at the transcriptional level [6,23,24]
and are therefore likely mediated by changes in the intensity or
duration of the intracellular signaling cascades triggered by the
inducing cytokines. Whether these forms of synergy are caused
by increased or prolonged activation of the same transcription
factors mobilized by the individual cytokines, the activation of
new transcriptional cascades, or the induction of new target genes
whose expression requires multiple transcriptional pathways to be
active, however, remains unknown. In contrast, ‘synergy by inde-
pendent action’ occurs post-transcriptionally and its effectiveness
in the context of a given induced anti-viral state likely depends
of a large array of variables including: cell type, which cytokines
were used, and which virus is being restricted. Unfortunately, very
few of these variables have been explored in a meaningful fashion.
A variety of other mechanisms to explain the synergistic inhibi-
tion of viral replication have also been proposed, such as one cyto-
kine altering expression of the receptor for a second cytokine
[25,26] and a role for possible secondary secretion of soluble
factors [27]; however, the breadth and impact of these potential
mechanisms remains difﬁcult to evaluate.4. Looking forward
Most of the work on the synergistic anti-viral effects of TNF and
IFN’s has focused on the ability of this phenomenon to restrict viral
replication in vitro. However, while a variety of groups have shown
that treatment of cells with TNF and IFN’s can synergistically
restrict the replication of a wide variety of viruses in culture
(reviewed in [15]) relatively little work has been done to deter-
mine the practical implications of this phenomenon.
One potential practical use for cytokine synergy could be to im-
prove current cytokine based therapies. For example, soluble IFN is
frequently used clinically as both an anti-viral [28] and/or anti-
cancer agent [29,30]. Unfortunately, this treatment is highly toxic
when used at clinically effective concentrations. A recent report
by Sainz et al. however, demonstrated that treatment with IFN-a
in combination with IFN-c provides signiﬁcantly improved protec-
tion to mice subjected to a lethal challenge with herpes simplex
virus type-1 at much lower IFN dosages then normally required
[19]. This suggests that current cytokine based therapies might
be improved through an understanding and application of syner-
gistic cytokine interactions.
Cytokine synergy might also play a key role in determining the
species tropism of certain viruses. For example, MYXV, which is
currently under investigation in our lab as a potential oncolytic
agent for the treatment of a variety of human malignancies [31–
37], is highly infectious in rabbits [38] but is unable to replicate
or cause pathology in vivo in any known non-rabbit species
[38,39]. In cultured primary murine ﬁbroblasts this restriction is
caused by the rapid induction of the canonical type-I IFN response
[40]. Genetic compromise of this interferon response, for example
through abrogation of STAT1 signaling, renders murine cells
permissive to MYXV infection and causes mice to become suscep-
tible to lethal MYXV infection following intracranial injection [40].
In primary human ﬁbroblasts, however, treatment with IFN-b
alone retards, but does not completely block MYXV replication
[6]. In these cells, a complete blockade of MYXV replication can
be accomplished only by treatment with combinations of cyto-
kines, such as IFN-b/IFN-c or IFN-b/TNF, which are likely bothsecreted from local infected myeloid cells, particularly macro-
phages. This suggests that complete restriction of MYXV in
humans, which occurs following deliberate injection of live virus
into volunteers [39], and could also occur following bites by
MYXV-bearing mosquitoes or during MYXV-based oncolytic viro-
therapy, might require synergistic cytokine responses.
A third role for cytokine synergy could be in preventing cellular
malignant transformation. It has been shown that the ability to in-
duce a synergistic transcriptional program has been speciﬁcally
lost in a wide variety of human cancer cells [24]. Additionally,
while the proliferation of normal primary cells can be completely
blocked by treatment with various cytokine combinations, these
same combinations have signiﬁcantly reduced cytostatic effects
on virtually all transformed cells [24]. While highly preliminary,
these data suggest that escape from the anti-proliferative effects
of cytokine synergy might be an important step towards cellular
transformation. Additionally, the ability of the induced synergistic
anti-viral state to potently restrict viral replication, combined with
its apparent absence or compromise in so many transformed cells,
provides a molecular mechanism to explain the phenotypic ‘oncot-
ropism’ of many oncolytic virus candidates, including MYXV.
Clearly, cytokine synergy has the potential to play a major role
in a variety of practical applications. Despite being identiﬁed over
20 years ago, however, a multitude of questions remain unan-
swered. In the future, we hope additional attention is paid to the
role cytokine synergy plays in cellular processes, particularly onco-
genic transformation and the mediation of anti-pathogen defenses,
and that its potential clinical applications are explored more
thoroughly.
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